Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Apellis Pharmaceuticals, Inc. (APLS) had Consolidated Net Income/Loss of $-42.15M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$178.49M |
|
$-42.15M |
|
$13.63M |
|
$164.87M |
|
$211.78M |
|
$-33.29M |
|
$-8.40M |
|
$-41.69M |
|
$-41.69M |
|
$-42.15M |
|
$-42.15M |
|
|
Consolidated Net Income/Loss |
$-42.15M |
$-42.15M |
|
$-33.29M |
|
$-32.23M |
|
126.02M |
|
126.02M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$755.61M |
|
$2.12M |
|
$65.78M |
|
$821.39M |
|
$200.66M |
|
$454.04M |
|
$464.43M |
|
$665.09M |
|
$156.31M |
|
$156.31M |
|
$156.31M |
|
126.19M |
|
| Cash Flow Statement Financials | |
$-48.97M |
|
$-0.06M |
|
$6.83M |
|
$412.61M |
|
$371.47M |
|
$-41.15M |
|
$54.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.77 |
|
-- |
|
-- |
|
0.74 |
|
2.90 |
|
92.37% |
|
-18.65% |
|
-18.65% |
|
-- |
|
-23.35% |
|
-23.61% |
|
$-49.02M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
0.11 |
|
0.83 |
|
107.97 |
|
-26.97% |
|
-26.97% |
|
-5.13% |
|
-6.91% |
|
$1.24 |
|
$-0.39 |
|
$-0.39 |
|